Yang Zhou, PhD, MPH
Associate Research ScientistCards
About
Research
Publications
2025
Phospholipid scramblase 1 (PLSCR1) regulates interferon-lambda receptor 1 (IFN-λR1) and IFN-λ signaling in influenza A virus (IAV) infection
Yang A, Ramos-Rodriguez L, Sorkhdini P, Yang D, Norbrun C, Majid S, Lee S, Zhang Y, Holtzman M, Boyd D, Zhou Y. Phospholipid scramblase 1 (PLSCR1) regulates interferon-lambda receptor 1 (IFN-λR1) and IFN-λ signaling in influenza A virus (IAV) infection. ELife 2025, 14: rp104359. PMID: 41439508, PMCID: PMC12736948, DOI: 10.7554/elife.104359.Peer-Reviewed Original ResearchConceptsPhospholipid scramblase 1Influenza A Virus InfectionInfluenza A virusCiliated airway epithelial cellsInterferon-stimulated genesAirway epithelial cellsScramblase 1Epithelial cellsCell surfaceSingle-cell RNA sequencing dataProtein-protein interactionsA virusRNA sequencing dataVirus-host interactionsSusceptible to IAV infectionAnti-flu activityIFN-LInterferon lambda receptor 1Sequence dataAnti-influenza drugsIAV strainsPulmonary epithelial cellsTranscriptome analysisBody weight lossExpression compartmentsPhospholipid scramblase 1 (PLSCR1) regulates interferon-lambda receptor 1 (IFN-λR1) and IFN-λ signaling in influenza A virus (IAV) infection
Yang A, Ramos-Rodriguez L, Sorkhdini P, Yang D, Norbrun C, Majid S, Lee S, Zhang Y, Holtzman M, Boyd D, Zhou Y. Phospholipid scramblase 1 (PLSCR1) regulates interferon-lambda receptor 1 (IFN-λR1) and IFN-λ signaling in influenza A virus (IAV) infection. ELife 2025, 14 DOI: 10.7554/elife.104359.3.Peer-Reviewed Original ResearchPhospholipid scramblase 1Influenza A Virus InfectionInfluenza A virusCiliated airway epithelial cellsInterferon-stimulated genesAirway epithelial cellsScramblase 1Epithelial cellsCell surfaceSingle-cell RNA sequencing dataProtein-protein interactionsA virusRNA sequencing dataVirus-host interactionsSusceptible to IAV infectionAnti-flu activityIFN-LInterferon lambda receptor 1Sequence dataAnti-influenza drugsPulmonary epithelial cellsIAV strainsTranscriptome analysisBody weight lossExpression compartmentsEvolving incidence patterns for locally advanced operable breast cancer by receptor status: SEER 2010–2021
Thomas A, Rhoads A, Mayer E, O’Reilly S, Harbeck N, Curigliano G, Zhou Y, Adam V, Chan N, Conway K, Ignatiadis M, Kalinsky K, DeMichele A, Romitti P. Evolving incidence patterns for locally advanced operable breast cancer by receptor status: SEER 2010–2021. Npj Breast Cancer 2025, 11: 127. PMID: 41233330, PMCID: PMC12615583, DOI: 10.1038/s41523-025-00835-7.Peer-Reviewed Original ResearchHR-positive breast cancerBreast cancerSurveillance, EpidemiologyLocally advanced operable breast cancerEarly-stage breast cancerRisk assessment toolAxillary lymph node dissectionHR-positive/HER2-negativeLocally advanced diseaseOperable breast cancerInvasive lobular cancerLymph node dissectionReceptor-based subtypesIncidence patternsAssessment toolDisease burdenChemotherapy useLobular cancerNode dissectionReceptor statusClinical questionsChemotherapy benefitAdvanced diseaseHR-positiveAnatomical disease burdenVirtual Compound Screening for Discovery of Dopamine D1 Receptor Biased Allosteric Modulators
Zhou Y, Wetsel W, Olson S, Barak L. Virtual Compound Screening for Discovery of Dopamine D1 Receptor Biased Allosteric Modulators. Journal Of Chemical Information And Modeling 2025, 65: 9713-9722. PMID: 40934869, PMCID: PMC12478865, DOI: 10.1021/acs.jcim.5c00972.Peer-Reviewed Original ResearchConceptsVirtual compound screeningAllosteric compoundsDopamine D1 receptorsSide effect profileCentral nervous system disordersChemical librariesTreatment of PDIntracellular loop 2Nervous system disordersD1 receptorsDopamine receptorsParkinson's diseaseD1RG protein activationPD therapySide effectsSystem disordersCompound screeningGold standardDrug screening platformDrug activityTherapeutic targetCompoundsL-DOPAAllosteric modulatorsWhen Autophagy Fails: ATG7 Variants and Their Impact on Radiation Lung Injury
Yang A, Zhou Y. When Autophagy Fails: ATG7 Variants and Their Impact on Radiation Lung Injury. American Journal Of Respiratory Cell And Molecular Biology 2025, 73: 163-165. PMID: 39903843, PMCID: PMC12334875, DOI: 10.1165/rcmb.2025-0006ed.Peer-Reviewed Original ResearchThe Specific Role of Stratifin in the Pathogenesis of Transforming Growth Factor-β-stimulated Pulmonary Fibrosis
Sadanaga T, Siegel Z, Jeong H, Kamle S, Ma B, Zhou Y, Elias J, Lee C. The Specific Role of Stratifin in the Pathogenesis of Transforming Growth Factor-β-stimulated Pulmonary Fibrosis. American Journal Of Respiratory And Critical Care Medicine 2025, 211: a7634-a7634. DOI: 10.1164/ajrccm.2025.211.abstracts.a7634.Peer-Reviewed Original ResearchPhospholipid scramblase 1: a frontline defense against viral infections
Yang A, Norbrun C, Sorkhdini P, Zhou Y. Phospholipid scramblase 1: a frontline defense against viral infections. Frontiers In Cellular And Infection Microbiology 2025, 15: 1573373. PMID: 40248364, PMCID: PMC12003403, DOI: 10.3389/fcimb.2025.1573373.Peer-Reviewed Original ResearchConceptsPhospholipid scramblase 1Human immunodeficiency virusInfluenza A virusToll-like receptor 9Human T-cell leukemia virus type 1Epstein-Barr virusHepatitis B virusInterferon-stimulated genesViral infectionHuman cytomegalovirusVirus type 1Antiviral activityTranslocation of phospholipidsFrontline defenseTransactivation of human immunodeficiency virusImmunodeficiency virusActivation of JAK/STAT pathwayImmune cellsSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2A virusB virusReceptor 9Respiratory syndrome coronavirus 2Entry of severe acute respiratory syndrome coronavirus 2Citrus pectin-coated inhalable PLGA nanoparticles for treatment of pulmonary fibrosis
Perera K, Ghumman M, Sorkhdini P, Norbrun C, Negash S, Zhou Y, Menon J. Citrus pectin-coated inhalable PLGA nanoparticles for treatment of pulmonary fibrosis. Journal Of Materials Chemistry B 2025, 13: 3325-3339. PMID: 39918485, PMCID: PMC11804936, DOI: 10.1039/d4tb01682c.Peer-Reviewed Original ResearchConceptsAnti-fibrotic therapiesPulmonary fibrosisUpregulated markersGalectin-3Off-target effectsTransforming growth factor-bTreatment of pulmonary fibrosisA-smooth muscle actinBleomycin-induced fibrosisMarkers of fibrosisAnti-fibrotic drugsGrowth factor BDose-dependent mannerNanoparticles' abilityAnti-fibrotic activityFDA-approved therapeuticsInhalable nanocarriersFibrotic lung tissueProfibrotic markersMRC-5 lung fibroblastsTherapeutic efficacyMouse lungMuscle actinPLGA nanoparticlesLung tissue
2024
Further Optimizing Care of Patients With Operable Hormone Receptor–Sensitive Breast Cancer
Thomas A, Mayer E, DeMichele A, Harbeck N, Curigliano G, Ignatiadis M, Adam V, Zhou Y, Brown T, Gilham L, Chua B, Kalinsky K, Wolff A, O'Reilly S. Further Optimizing Care of Patients With Operable Hormone Receptor–Sensitive Breast Cancer. Journal Of Clinical Oncology 2024, 43: 487-491. PMID: 39383501, DOI: 10.1200/jco.24.01080.Peer-Reviewed Original Research322P Incidence patterns for locally advanced operable breast cancer by receptor status: SEER 2010-2021
Thomas A, Rhoads A, O'Reilly S, Mayer E, Harbeck N, Curigliano G, Zhou Y, Adam V, Chan N, DeMichele A, Ignatiadis M, Kalinsky K, Romitti P. 322P Incidence patterns for locally advanced operable breast cancer by receptor status: SEER 2010-2021. Annals Of Oncology 2024, 35: s350. DOI: 10.1016/j.annonc.2024.08.261.Peer-Reviewed Original Research
Clinical Trials
Current Trials
Determining Mechanisms of Sensitivity and Resistance to Anti-Cancer Therapy for Advanced Lung Cancer
HIC ID1603017333RoleSub InvestigatorPrimary Completion Date06/20/2026Recruiting Participants
News
News
Get In Touch
Contacts
Email